Search

Displaying results 2311 - 2320 of 10000 in total
  1. Drug

    Artenimol

    go.drugbank.com/drugs/DB11638
    ApprovedInvestigational

    Artenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated *Plasmodium falciparum* infections [FDA Label]. … It was first authorized for market by the European Medicines Agency in October 2011 in combination with [DB13941] as the product Eurartesim.

    Categories: Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors
  2. Drug

    Arbekacin

    go.drugbank.com/drugs/DB06696
    Investigational

    An semisynthetic aminoglycoside antibiotic. Often used for treatment of multi-resistant bacterial infection such as methicillin-resistant _Staphylococcus aureus_ (MRSA).

    Categories: Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index
  3. Drug

    Binimetinib

    go.drugbank.com/drugs/DB11967
    ApprovedInvestigational

    detected by an FDA-approved test. … Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index
  4. Drug

    Pralatrexate

    go.drugbank.com/drugs/DB06813
    ApprovedInvestigational

    [A246703] As such, pralatrexate is thought to have a better therapeutic window compared to other antifolate analogs due to the novel target of RFC. … [A246693] Pralatrexate is designed to have a higher affinity for the reduced folate carrier, a protein that is overexpressed in malignant cells and is upregulated by oncogenes.

  5. Drug

    Iptacopan

    go.drugbank.com/drugs/DB16200
    ApprovedInvestigational

    Iptacopan is a small-molecule factor B inhibitor previously investigated as a potential treatment for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) by inhibiting the complement factor … [A262566] Factor B is a positive regulator of the alternative complement pathway, where it activates C3 convertase and subsequently C5 convertase.

    Categories: Compounds used in a research, industrial, or household setting, Cytochrome P-450 Substrates
  6. Drug

    Metergoline

    go.drugbank.com/drugs/DB13520
    Approved

    Metergoline is an antagonist at various 5-HT receptor subtypes at a relatively low concentration and agonist at dopamine receptors. … Metergoline is an ergot-derived psychoactive drug that acts as a ligand for serotonin and dopamine receptors.

  7. Drug

    Chymopapain

    go.drugbank.com/drugs/DB06752
    ApprovedWithdrawn

    [L2482]It is an extracellular plant cysteine proteinase similar to papain in specificity.[A32688] Chymopapain was developed by Chart Medcl and FDA approved on November 10, 1982.

  8. Drug

    Omidenepag isopropyl

    go.drugbank.com/drugs/DB15071
    Approved

    The use of an EP2 receptor agonist such as omidenepag represents an alternative in these scenarios. Omidenepag IOP-lowering effect is comparable to the one observed with [latanoprost]. … Omidenepag isopropyl is a topical ocular hypotensive agent used to reduce intraocular pressure (IOP) in patients with glaucoma and ocular hypertension.

  9. Drug

    Iroxanadine

    go.drugbank.com/drugs/DB05444
    Experimental

    BRX-235 (iroxanadine) is a a novel small molecule synthesized by Biorex, Hungary that acts as a cardioprotective agent. … It induces phosphorylation of p38 SAPK, which plays an important role in EC homeostasis. endothelial cell (EC).

  10. Drug

    Sonidegib

    go.drugbank.com/drugs/DB09143
    ApprovedInvestigational

    Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma.

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Substrates